Artificial Intelligence

Female researcher in a laboratory
#Artificial intelligence (AI) #Drug discovery #Eli Lilly #Insilico Medicine

Insilico partners with Eli Lilly on AI drug discovery 

Drug discovery company Insilico Medicine has entered a research collaboration with pharmaceutical giant Eli Lilly to advance AI-driven drug discovery.  Insilico will use its validated Pharma.AI platform to generate, design, and optimise candidate compounds against targets defined under the agreement.   The company is eligible to… Read More

#Business & Investment #News

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #Google #Immunotherapy

DDW Highlights: 28 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, Galapagos announced plans to shelve its cell therapy business and hundreds of… Read More

#Podcasts

#Artificial intelligence (AI) #Cell Science #Drug discovery

Innovative AI software solutions driving biomarker research – custom webinar with Danaher Oct 2025

Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. This webinar, hosted by DDW and supported by Danaher Life Sciences, explores how advanced platforms such as Genedata Profiler… Read More

#Webinars

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #DDW Turning Science into Business Symposium #Google #Immunotherapy

This week in Drug Discovery (20 – 24 October)

News round-up for 20 – 24 October by Bruno Quinney, Content Team at DDW.  This week’s leading story comes from biotech, with Galapagos announcing plans to shelve its cell therapy business and hundreds of employees set to lose theirjobs. Elsewhere, pharma firms are offering discounts to US… Read More

#News

Enzymes
#Artificial intelligence (AI) #Enzymes #Genomics

IDT and Profluent Bio partner on AI-driven next-gen enzymes

Genomics company Integrated DNA Technologies (IDT) has announced a strategic partnership with AI-first protein design Profluent Bio to design and optimise next-generation enzymes.  The collaboration will bring together Profluent’s generative AI platform with IDT’s expertise in enzymology and genomics, with the aim of exploring new paths for… Read More

#Business & Investment #News

Neural networks
#Artificial intelligence (AI) #Flagship Pioneering #Small molecules

Flagship Pioneering unveils $50 million AI platform

Biotechnology company Flagship Pioneering has unveiled its generative AI platform Expedition Medicines, backed by $50 million in funding.  Flagship believes Expedition Medicines will push the boundaries in medicine to enable the creation of first-in-class therapies across oncology, immunology and other diseases. The platform can learn the rules… Read More

#Business & Investment #News

Map of China
#Artificial intelligence (AI) #China #Metabolic diseases #Oncology

Is China the next global biopharma powerhouse?

Regulatory reform and investment in innovation have supercharged China’s biopharma sector, but will ongoing trade wars with the US pose a risk to growth? By Diana Turner. China’s role in the global biopharma sector has grown significantly in recent years. It is the world’s largest supplier of active… Read More

#Exclusive Content #Market Reports

Human brain
#Artificial intelligence (AI) #Automation #Deep learning #Drug discovery #eBook #Machine learning

eBook: AI – Advancing drug discovery and development

Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation. “AI is evolving faster than any other lab technology with new models and… Read More

#News

#Artificial intelligence (AI) #Drug discovery

AI – Advancing drug discovery and development

Over the last few years artificial intelligence (AI) has emerged as a key trend and an important area for investment in drug discovery, whether in preclinical research workflows, clinical trial design or regulation. This eBook, sponsored by BioIVT, explores the latest AI developments impacting drug discovery, the research areas most… Read More

#DDW eBooks

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Lab of the future #Lab technology #Pistoia Alliance

Survey says AI leads investment, but lack of skills a barrier

The use of artificial intelligence (AI) continues to rise, according to the results of the Pistoia Alliance’s annual Lab of the Future survey.  The results show that 77% of respondents expect to use AI in the next two years. It also remains the number one investment area… Read More

#News

Business financing
#Artificial intelligence (AI) #Drug development #Drug discovery #Financing

Tres Alchemix closes $4.4 million financing round

AI-driven biotechnology company Tres Alchemix has closed its $4.4 million Series A financing round, the company has announced.  New funding will be used to accelerate the development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a… Read More

#Business & Investment #News #Start-up Zone